Famotidine and calcium carbonate drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Famotidine and Calcium Carbonate Drug Interactions: Pharmacokinetics and Clinical Implications
Pharmacokinetic Interactions Between Famotidine and Calcium Carbonate
Research shows that when famotidine is administered together with calcium carbonate (often in fixed-dose combination formulations), there is no significant effect on the pharmacokinetics of famotidine. Plasma concentration profiles, maximal concentration (Cmax), and area under the curve (AUC) for famotidine remain similar whether or not calcium carbonate is co-administered, indicating that calcium carbonate does not significantly alter the absorption or bioavailability of famotidine in healthy individuals .
Detection and Clinical Relevance of Drug-Drug Interactions
Community pharmacy studies have identified minor drug-drug interactions between famotidine and calcium carbonate, but these are generally considered clinically insignificant. Most drug interaction databases classify this interaction as minor, and it is not consistently detected across all platforms. Overall, antacid-induced drug interactions, including those involving famotidine and calcium carbonate, are usually moderate and not a major clinical concern .
Effects on Phosphate Binding in Hemodialysis Patients
In patients undergoing hemodialysis, the interaction between famotidine and calcium carbonate becomes more clinically relevant. Several studies have found that co-administration of famotidine with calcium carbonate can reduce the phosphate-binding efficacy of calcium carbonate. This leads to increased serum phosphate levels, which can be problematic for patients with chronic kidney disease. The effect is dose-dependent and has been observed even at recommended doses of famotidine for hemodialysis patients 345. Switching from calcium carbonate to calcium lactate as a phosphate binder in these patients can mitigate the increase in serum phosphate, as famotidine does not affect the phosphate-binding ability of calcium lactate .
Impact on Calcium Absorption
There is evidence that famotidine can increase intragastric pH, which may reduce the solubility and absorption of calcium from calcium carbonate. This effect has been observed in case reports, where co-administration of famotidine led to decreased serum calcium levels and symptoms of hypocalcemia, which resolved after discontinuing famotidine . This suggests that in patients who rely on calcium carbonate for calcium supplementation, famotidine may impair calcium absorption and lead to clinically significant hypocalcemia in susceptible individuals.
Comparative Acid-Reducing Effects
Famotidine and calcium carbonate have different profiles in terms of acid reduction. Calcium carbonate acts quickly but has a short duration, while famotidine has a slower onset but a much longer duration of action. Their peak acid-reducing effects are similar, but the timing and duration differ, which may influence how they are used together for symptom control .
Conclusion
In healthy individuals, famotidine and calcium carbonate do not significantly interact in a way that alters famotidine’s pharmacokinetics. However, in patients with chronic kidney disease or those dependent on calcium supplementation, famotidine can reduce the effectiveness of calcium carbonate as a phosphate binder and may impair calcium absorption, potentially leading to increased serum phosphate or decreased serum calcium. These effects are most relevant in specific patient populations and should be monitored closely. For most people, the interaction is minor and not clinically significant, but caution is warranted in those with special medical needs 123457.
Sources and full results
Most relevant research papers on this topic